Jim Cramer makes the call on a few caller favorite stocks.» Read More
There are reports of booze, women and beads--as in Mardi Gras beads. Specifically, the piece cites allegations from a lawsuit brought by a former MDT attorney who says the medical device maker sponsored a "discussion group" outing to New Orleans.
A first-of-its-kind study shows that putting hundreds of thousands of American heart patients on drugs instead of giving them a stent could save the country billions of dollars a year.
Not too long ago, some had written off the potential for significant growth to resume in sales of the little wire mesh tubes that are painted with special drugs to help keep arteries from reclogging.
The Lightning Round is extended in this CNBC.com exclusive feature.
Even with the overall stock market struggling to post gains, there are always winners somewhere. Carter Worth reveals where!
Cory Scott is a second-semester MBA student at the Walton College of Business at the University of Arkansas. He's already wading into the tricky waters of managing investments. There's about $350,000 in his fund, the student-managed Shollmier Fund, and it's up an average of 7.5 percent per year over the last three years.
Following are the day’s biggest winners and losers. Find out why shares of Medtronic and Reliance Steel popped while Las Vegas Sands and Starbucks dropped.
Gerald Jordan, portfolio manager at Jordan Opportunity Fund said that investing in large cap stocks is the way to go.
Fast Money Now – the trades you need while the market is open.
A new study and an editorial in a major medical journal could reignite the debate over whether drugs or stents or a combination of both are better for the millions of Americans with heart trouble.
The health-care sector has been getting healthier, according to Schwab's Paul Alan Davis.
Health care stocks have been the stealth performers, and they will likely continue to outperform because of steady earnings, a favorable macro environment and cheap valuations, says Merrill Lynch's Brian Belski.
Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.
Ed Sheidlower is avoiding financials. But the Bryce Capital Management portfolio manager sees other sectors -- and stocks -- as good investments.
To give investors an edge, CNBC asked the experts for their best stock picks now.
Abbott Laboratories Wednesday said second-quarter earnings jumped 34 percent, beating its expectations, fueled by sizzling sales of its medical devices, Humira arthritis treatment and other drugs.
To give investors an edge in this volatile market environment, CNBC asked the experts for their best trades now.
At a time of market uncertainty, what can an investor count on? Knee replacements, for one thing. Bruce Nudell, UBS senior research analyst, takes that as his cue in picking some promising stocks.
By anyone's reckoning, it was a rough week. Crude oil continued its relentless climb; banks and brokerages gave hints of more discouraging news; government data pointed to a weak economy; even strong companies like Nike, Oracle, and Research In Motion issued cautious guidance; and Federal Reserve policymakers, widely perceived as powerless to help, left interest rates unchanged. But all week, even through the worst of the market's sell-offs, CNBC guests offered
FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."